These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30796704)

  • 1. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
    Holowka S; Shroff M; Chavhan GB
    Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
    Bäuerle T; Saake M; Uder M
    Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
    Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
    Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Contrast Material Use in Children.
    Soares BP; Lequin MH; Huisman TAGM
    Magn Reson Imaging Clin N Am; 2017 Nov; 25(4):779-785. PubMed ID: 28964467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium-based contrast agents in children.
    Rozenfeld MN; Podberesky DJ
    Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
    Ponrartana S; Moore MM; Chan SS; Victoria T; Dillman JR; Chavhan GB
    Pediatr Radiol; 2021 May; 51(5):736-747. PubMed ID: 33871726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
    Penfield JG; Reilly RF
    Semin Dial; 2011; 24(5):480-6. PubMed ID: 21913988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI.
    Costelloe CM; Amini B; Madewell JE
    Semin Ultrasound CT MR; 2020 Apr; 41(2):170-182. PubMed ID: 32446430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
    Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
    Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.
    McDonald JS; McDonald RJ
    Magn Reson Imaging Clin N Am; 2020 Nov; 28(4):497-507. PubMed ID: 33040991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice.
    Meng H; Grosse-Wortmann L
    J Cardiovasc Magn Reson; 2012 Aug; 14(1):56. PubMed ID: 22871150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.
    Penfield JG
    Pediatr Nephrol; 2008 Dec; 23(12):2121-9. PubMed ID: 18543004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The need for prophylactic hemodialysis to protect against nephrogenic systemic fibrosis in patients with end-stage renal disease receiving gadolinium-based contrast agents.
    Lee Y; Kim J; Kwon S; Jeong JC; Joo KW; Oh KH
    Acta Radiol; 2023 Aug; 64(8):2492-2496. PubMed ID: 37128169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
    Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
    Larson KN; Gagnon AL; Darling MD; Patterson JW; Cropley TG
    JAMA Dermatol; 2015 Oct; 151(10):1117-20. PubMed ID: 26017458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.
    Mathur M; Jones JR; Weinreb JC
    Radiographics; 2020; 40(1):153-162. PubMed ID: 31809230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
    Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
    Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.